HealthEquity overview after recent trading move

HealthEquity (HQY) has drawn fresh investor attention after a recent trading move, with the stock last closing at US$82.45. That price offers a starting point for assessing its current valuation and fundamentals.

The 6.04% one-day share price return follows a softer run. The year-to-date share price return shows a 9.47% decline and the one-year total shareholder return shows a 2.31% decline, which contrasts with the stronger three-year total shareholder return of 52.63%. This suggests that longer-term holders have still seen meaningful gains, even as near-term momentum has faded.

If you are looking beyond HealthEquity and want to see where else sentiment and fundamentals might be lining up, take a look at the screener for 33 healthcare AI stocks

HealthEquity now trades at US$82.45, with implied discounts to both analyst targets and one intrinsic value estimate. Is the recent pullback offering you an undervalued entry point, or is the market already pricing in future growth?

Most Popular Narrative: 27% Undervalued

At a last close of $82.45 versus a narrative fair value of $112.88, HealthEquity is framed as meaningfully undervalued, with the story anchored on long term HSA growth and margin support.

The recent regulatory expansion, allowing direct primary care, pre deductible telehealth, and millions of new ACA bronze/catastrophic plan members to qualify for HSAs, creates the largest addressable market increase in two decades, poised to accelerate new account openings and AUM growth, meaningfully boosting future revenue.

Curious how that projected HSA surge translates into future earnings power and a higher fair value, the narrative leans on specific growth, margin, and valuation assumptions that are not baked into the current share price.

Result: Fair Value of $112.88 (UNDERVALUED)

However, the story could change if a weaker labor market caps new HSA account growth or if lower interest rates squeeze earnings from custodial cash yields.

Another angle on valuation

The earlier view leans on analyst forecasts and a narrative fair value, but the current P/E of 32.4x tells a different story. That multiple sits above peers at 27.3x, the US Healthcare average at 24.3x, and even an estimated fair ratio of 25.6x. This points to richer pricing and less margin for error if growth or sentiment cools.

To see what the numbers say about this price, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

The mixed signals on price and valuation only matter if you use them. Take a closer look at the underlying data, act quickly, and weigh it against the 4 key rewards.

Ready for more investing ideas?

If you stop with just one stock, you could miss opportunities that fit your goals even better. Use the Simply Wall St screener to pressure test fresh ideas.

• Spot potential value opportunities early by scanning screener containing 25 high quality undiscovered gems before they appear on everyone else's radar.
• Strengthen the quality of your watchlist by filtering companies through the solid balance sheet and fundamentals stocks screener (42 results) so financial resilience stays front and center.
• Target dependable income ideas by reviewing the 12 dividend fortresses that focus on higher yielding, income focused stocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.